Breaking News
Sort by:
Top Post
NHS Slashes Longest Elective and Cancer Patient Waiting Lists
The number of people waiting over 18 months for NHS care has fallen again despite […]
GSK Reaches Agreement to Acquire Late-stage Biopharmaceutical Company Sierra Oncology for $1.9bn
GlaxoSmithKline plc (LSE/NYSE: GSK) and Sierra Oncology, Inc (Nasdaq: SRRA) today announced that the companies […]
GSK Announces Positive Phase III Efficacy and Safety Data for Daprodustat in Patients with Anaemia Due to Chronic Kidney Disease
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive results from the Phase III ASCEND (Anaemia Studies in […]
Medicago and GSK Announce Positive Interim Phase 2 Results for Adjuvanted Covid-19 Vaccine Candidate
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to report […]
GSK and VIR Biotechnology EMA Rolling Review of VIR-7831 (Sotrovimab)
GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced that the European Medicines Agency (EMA) has […]
EU Commission Approves Benlysta for Lupus Nephritis
GlaxoSmithKline plc (GSK) today announced the European Commission has approved the expanded use of intravenous […]
ViiV Healthcare New Drug Application for Long-Acting Cabotegravir for Prevention of HIV
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer […]
FDA Grants Accelerated Approval for GSK’s JEMPERLI (dostarlimab-gxly) for Women with Recurrent or Advanced dMMR Endometrial Cancer
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has […]
Lilly, Vir, GSK Announce Positive Topline Data from Phase 2 BLAZE-4 Trial
Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced […]
- Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa Read more
- Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors Read more
- Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics Read more
- Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer Read more
- Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases Read more